Drug: Aminosyn II 3.5% in 25% Dextrose

Upper Chamber: Aminosyn II 7%, an amino acid injection, 500 mL. Aminosyn II 7% is a sterile, nonpyrogenic solution for intravenous infusion. The formulation is described in the table below. Lower Chamber: 50% Dextrose Injection, USP, 500 mL. 50% Dextrose Injection, USP (concentrated dextrose in water) is a sterile, nonpyrogenic, hypertonic solution of Dextrose, USP in water for injection. The table below indicates the characteristics of this concentrated solution. The container must be used only after removing the clamp and thoroughly mixing the contents of the two chambers. The solution resulting from mixing the contents of the upper and the lower chamber will be 3.5% amino acids in 25% dextrose. Mixing the contents of the upper and lower chambers yields a concentrated source of amino acids and carbohydrate calories for intravenous infusion. Headspace contains Nitrogen gas. The composition of this admixture is described in the table below.   Solution Composition per 100 mL Upper
Chamber Lower
Chamber Admixture Dextrose, hydrous (g)   50 25 Essential Amino Acids (mg)   Isoleucine 462   231   Leucine 700   350   Lysine (as acetate salt)* 735   368   Methionine 120   60   Phenylalanine 209   104   Threonine 280   140   Tryptophan 140   70   Valine 350   175 Nonessential Amino Acids (mg)   Alanine 695   348   Arginine 713   356   L-Aspartic Acid 490   245   L-Glutamic Acid 517   258   Histidine 210   105   Proline 505   252   Serine 371   186   N-Acetyl-L-Tyrosine 189   94   Glycine 350   175 Total Amino Acids (g) 7   3.5 Protein Equivalent (g) 7   3.5 Total Nitrogen (g) 1.07   0.54 Electrolytes (mEq/liter)   Sodiuma (Na+) 36   18   Acetateb (C2H3O2–) 50.3   25.2   Sodium hydrosulfite (mg/100 mL) 60   30 Osmolarity mOsmol/liter (actual) 647 1997 1515 pH 5.8 4.3 5.8 range 5.0 to 6.5c 3.2 to 6.5 5.0 to 6.5 *Amount cited is for lysine alone and does not include the acetate salt.
a Includes sodium from the pH adjustor sodium hydroxide and the antioxidant, sodium hydrosulfite.
b Includes acetate from lysine acetate.
c May contain sodium hydroxide for pH adjustment. The formulas for the individual amino acids present are as follows: Essential Amino Acids Isoleucine CH3CH2CH(CH3)CH(NH2)COOH Leucine (CH3)2CHCH2CH(NH2)COOH Lysine Acetate H2N(CH2)4CH(NH2)COOH • CH3COOH Methionine CH3S(CH2)2CH(NH2)COOH Phenylalanine
CH2CH(NH2)COOH Threonine CH3CH(OH)CH(NH2)COOH Tryptophan
CH2CH(NH2)COOH Valine (CH3)2CHCH(NH2)COOH Nonessential Amino Acids Alanine CH3CH(NH2)COOH Arginine H2NC(NH)NH(CH2)3CH(NH2)COOH L-Aspartic Acid HOOCCH2 CH(NH2)COOH L-Glutamic Acid HOOC(CH2)2CH(NH2)COOH Glycine H2NCH2COOH Histidine
CH2CH(NH2)COOH Proline Serine HOCH2CH(NH2)COOH N-Acetyl-L-Tyrosine a Includes sodium from the pH adjustor sodium hydroxide and the antioxidant, sodium hydrosulfite.
b Includes acetate from lysine acetate.
c May contain sodium hydroxide for pH adjustment. Dextrose, USP is chemically designated D-glucose, monohydrate (C6H12O6 • H20), a hexose sugar freely soluble in water. The flexible plastic container is fabricated from a specially formulated nonplasticized thermoplastic co-polyester (CR3). Water can permeate from inside the container into the overwrap but not in amounts sufficient to affect the solution significantly. Solutions inside the plastic container also can leach out certain of its chemical components in very small amounts before the expiration period is attained. However, the safety of the plastic has been confirmed by tests in animals according to USP biological standards for plastic containers.Last reviewed on RxList: 1/14/2009
This monograph has been modified to include the generic and brand name in many instances.

Source: http://www.rxlist.com

Hyperosmolar syndrome, resulting from excessively rapid administration of concentrated dextrose may cause mental confusion and/or loss of consciousness. Reactions which may occur because of the solution or the technique of administration include febrile response, infection at the site of injection, venous thrombosis or phlebitis extending from the site of injection, extravasation and hypervolemia. Generalized flushing, fever and nausea also have been reported during peripheral infusions of amino acid solutions. If an adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate therapeutic countermeasures and save the remainder of the fluid for examination if deemed necessary. Read the Aminosyn II 3.5% in 25% Dextrose (amino acid injection in dextrose injection) Side Effects Center for a complete guide to possible side effectsLearn More »

Source: http://www.rxlist.com

The total daily dose of Aminosyn II 3.5% in 25% Dextrose (amino acid injection in dextrose injection) Injection to be infused depends on daily protein and caloric requirements and on the patient's metabolic and clinical response. In many patients, provision of adequate calories in the form of hypertonic dextrose may require the administration of exogenous insulin to prevent hyperglycemia and glycosuria. To prevent rebound hypoglycemia, a solution containing 5% dextrose should be administered when hypertonic dextrose infusions are abruptly discontinued. As reported in the literature, the dosage and constant infusion rate of intravenous dextrose must be selected with caution in pediatric patients, particularly neonates and low birth weight infants, because of the increased risk of hyperglycemia/ hypoglycemia. As with all intravenous fluid therapy, the parenteral administration of a solution of amino acids and dextrose requires an accurate estimate of the total fluid, electrolytes and acid-base needed to compensate for the patient's measurable urinary and other (i.e., nasogastric suction, fistula drainage, diarrhea) daily losses. After estimating the total daily fluid (water) requirements, the appropriate volume to be infused to meet the daily protein requirement of the patient, can be determined. The balance of fluid needed beyond the volume of the amino acid/dextrose solution can be provided by other solutions suitable for intravenous infusion. I.V. lipid emulsions may also be infused to deliver additional calories if required. Lipid emulsion can be administered to provide up to 3 g fat/kg/day, infused simultaneously with Aminosyn II 3.5% in 25% Dextrose (amino acid injection in dextrose injection) Injection by means of a Y-connector located near the infusion site, using separate flow controls for each solution. Aminosyn II 3.5% in 25% Dextrose (amino acid injection in dextrose injection) Injection should not be premixed with fat emulsions. Vitamins and trace minerals may be added to the amino acid/dextrose solution as needed. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. The total daily dose of amino acid/dextrose solution to be infused depends on daily protein requirements and on the patient's metabolic and clinical response. The daily determination of nitrogen balance and accurate body weights, corrected for fluid balance, are probably the best means of assessing individual protein requirements. Adults The daily nutrient requirements of an average adult patient, not hypermetabolic, in an acceptable weight range and with restricted physical activity, are about 30 kcal/kg of body weight, 12 to 18 grams of nitrogen and between 2500 and 3000 mL of fluids. In depleted and severely traumatized patients such as burned patients or patients who have received major surgery with complications, the requirements for nutrients and fluids may be significantly higher. In such cases, 4000 calories and 25 grams of nitrogen or more may be required daily to achieve nitrogen balance. The fluid losses through drainages and wound surface must be taken into account in calculating the fluid requirements of these patients. Fat emulsion administration should be considered when prolonged parenteral nutrition is required in order to prevent essential fatty acid deficiency (EFAD). Serum lipids should be monitored for evidence of EFAD in patients maintained on fat-free TPN. Each gram of dextrose provides approximately 3.4 calories — 1000 mL of Aminosyn II 3.5% in 25% Dextrose Injection will provide 5.6 grams of nitrogen and 850 calories. The infusion rate of Aminosyn II 3.5% in 25% Dextrose (amino acid injection in dextrose injection) Injection should be 2 mL/min initially and may be gradually increased to deliver the required amounts of amino acids and calories. If nutrient administration falls behind schedule, under no circumstances should an attempt to “catch up” to planned intake be made. The rate of nutrient infusion is governed by the protein requirements and by the patient's glucose tolerance estimated by glucose levels in plasma and urine. The maximum rate at which dextrose can be infused without producing glycosuria is 0.5 g/kg/hour; at a rate of 0.8 g/kg/hour, about 95% of the infused dextrose is retained. Administration of exogenous insulin may be required in order to control hyperglycemia and glycosuria which may occur upon infusion of concentrated glucose solutions. When concentrated dextrose infusion is abruptly interrupted rebound hypoglycemia may occur, which can be prevented by the administration of 5% or 10% dextrose solutions. Part of the caloric requirements may be met by the infusion of I.V. fat emulsions. SERUM ELECTROLYTES SHOULD BE MONITORED AS INDICATED. Electrolytes should be added to the nutrient solution as indicated by the patient's clinical condition and laboratory determinations of plasma values. Major electrolytes are sodium, chloride, potassium, phosphate, magnesium and calcium. Adding 20 mL of TPN Electrolytes (List 5779) to the amino acid chamber and 5 mL of Potassium Phosphate (List 7296) to the dextrose chamber will result in final admixture concentrations (in mEq/L) as follows: 53 sodium, 42 potassium, 35 chloride, 5 magnesium, 4.5 calcium, 54.7 acetate, and 15 (mM) phosphate. Alternate electrolyte additives may be used at the clinician's discretion. Vitamins, including folic acid and vitamin K are required additives. The trace element supplements should be given when long-term parenteral nutrition is undertaken. Calcium and phosphorus are added to the solution as indicated. The usual dose of phosphate added to a liter of TPN solution (containing 25% dextrose) is 12 mM. This requirement is related to the carbohydrate calories delivered. Iron is added to the solution or given intramuscularly in depot form as indicated. Vitamin B12, vitamin K and folic acid are given intramuscularly or added to the solution as desired. Calcium and phosphate additives are potentially incompatible when added to the TPN admixture. However, if one additive is added to the amino acid solution, and the other to the concentrated dextrose solution, and if the contents of both chambers are mixed before they are combined, then the likelihood of physical incompatibility is reduced. In patients with hyperchloremic or other metabolic acidosis, sodium and potassium may be added as the acetate or lactate salts to provide bicarbonate alternates. In adults, hypertonic mixtures of amino acids and dextrose may be safely administered by continuous infusion through a central venous catheter with the tip located in the vena cava. Pediatric Pediatric requirements for parenteral nutrition are constrained by the greater relative fluid requirements of the infant and greater caloric requirements per kilogram. A 3.5% amino acid solution is too concentrated for use in pediatric patients less than 1 year old, who generally require a 2.5% amino acid solution. However, older pediatric patients can receive Aminosyn II 3.5% in 25% Dextrose (amino acid injection in dextrose injection) Injection. The suggested amino acid dosage level for children between 4 and 12 years of age is 2 g/kg/day; for 13 to 15 years of age, 1.7 g/kg/day; and for 16 years of age and above, 1.5 g/kg/day. Energy requirements for children between 1 and 7 years of age are approximately 75 to 90 kcal/kg/day; for children 7 to 12 years of age, 60 to 75 kcal/kg/day; and for ages 12 to 18 years, 30 to 60 kcal/kg/day. Energy intake may be supplemented with intravenous fat emulsion. In cases of malnutrition or stress, these requirements may be increased. Supplemental electrolytes and vitamin additives should be administered as deemed necessary by careful monitoring of blood chemistries and nutritional status. Iron supplementation is more critical in the child than the adult because of the increasing red cell mass required by the growing child. Serum lipids should be monitored for evidence of essential fatty acid deficiency in patients maintained on fat-free TPN. Bicarbonate should not be administered during infusion of the nutritional solution unless deemed absolutely necessary. To ensure the precise delivery of the small volumes of fluid necessary for total parenteral nutrition in children, accurately calibrated and reliable infusion systems should be used. Instructions for use DO NOT USE IF AMINOSYN II IS DISCOLORED OR IF CLAMP IS OPEN OR MISSING. COLOR VARIATION IN THE DEXTROSE INJECTION FROM PALE YELLOW TO YELLOW IS NORMAL AND DOES NOT ALTER EFFICACY. To Open Tear outer wrap at notch. After removing the overwrap, check for minute leaks by squeezing the container firmly. If leaks are found, discard solution as sterility may be impaired. If supplemental medication is desired, follow directions below before preparing for administration. To Add Medication
  1. Prepare the appropriate additive port.
  2. Using aseptic technique and an additive delivery needle of appropriate length, puncture resealable additive port at target area through inner diaphragm and inject. Withdraw needle after injecting medication.
  3. The additive ports should be protected by covering with additive caps.
  4. Mix container contents thoroughly.
Preparation for Administration (Use aseptic technique)
  1. Open clamp between the two chambers. Completely drain all the solution and air into the lower chamber. To achieve this, stretch the side wall of the emptied top chamber.
  2. Close flow control clamp of administration set.
  3. Remove cover from outlet port at bottom of container.
  4. Insert piercing pin of administration set into port with a twisting motion until the set is firmly seated. NOTE: See full directions on administration set carton.
  5. Suspend from hanger at top of container.
  6. Squeeze and release drip chamber to establish proper fluid level in chamber.
  7. Open flow control clamp to expel air from set. Close flow control clamp.
  8. Connect to central infusion catheter.
  9. Regulate rate of administration with flow control clamp. Ensure that all solution and air are in the lower chamber when reading fluid levels.
WARNING: Do not use flexible container in series connections.

Source: http://www.rxlist.com

Additives may be incompatible. Consult with pharmacist, if available. When introducing additives, use aseptic technique, mix thoroughly and do not store. Last reviewed on RxList: 1/14/2009
This monograph has been modified to include the generic and brand name in many instances.

Source: http://www.rxlist.com

Aminosyn II 3.5% in 25% Dextrose Injection is indicated for central vein infusion in the prevention of nitrogen loss and negative nitrogen balance in cases where (a) the gastrointestinal tract by the oral, gastrostomy or jejunostomy route cannot or should not be used, (b) gastrointestinal absorption of nutrients is impaired or (c) metabolic requirements for protein and calories are substantially increased as with extensive burns and (d) morbidity and mortality may be reduced by replacing amino acids lost from tissue breakdown, thereby preserving tissue reserves, as in acute renal failure. In such patients intravenous feeding for more than a few days would be expected. The addition of supplemental electrolytes, will be required in accordance with the prescription of the attending physician.

Source: http://www.rxlist.com

This preparation should not be used in patients with hepatic coma or metabolic disorders involving impaired nitrogen utilization. Last reviewed on RxList: 1/14/2009
This monograph has been modified to include the generic and brand name in many instances.

Source: http://www.rxlist.com

In the event of overhydration or solute overload, re-evaluate the patient and institute appropriate corrective measures. See WARNINGS and PRECAUTIONS.

Source: http://www.rxlist.com

Aminosyn® II 3.5% (amino acid injection in dextrose injection) in 25% Dextrose Injection is supplied in a 1000 mL volume dual-chamber flexible container. (List No. 7700). Aminosyn II 3.5% in 25% Dextrose (amino acid injection in dextrose injection) Injection is obtained by opening the clamp separating the two chambers and mixing the contents of the upper chamber, 500 mL of Aminosyn II 7% and the lower chamber, 500 mL of 50% Dextrose Injection, USP. Exposure of pharmaceutical products to heat should be minimized. Avoid excessive heat. Protect from freezing. It is recommended that the product be stored at room temperature (25°C); however, brief exposure up to 40°C does not adversely affect the product. Avoid exposure to light. To prevent breakage, handle cold or refrigerated (2°C to 8°C) co-polyester (CR3) containers with care. Hospira, Inc., Lake Forest, IL 60045 USA. Revised: May, 2004. FDA revision date: 6/23/2003 Last reviewed on RxList: 1/14/2009
This monograph has been modified to include the generic and brand name in many instances.

Source: http://www.rxlist.com

Special care must be taken when administering concentrated glucose to diabetic or prediabetic patients. To control and minimize hyperglycemia and consequent glycosuria, it is desirable to monitor blood and urine glucose and, if necessary, add insulin. Because of its antianabolic activity, concurrent administration of tetracycline may reduce the nitrogen sparing effects of infused amino acids. Feeding regimens which include amino acids should be used with caution in patients with history of renal disease, pulmonary disease, or with cardiac insufficiency so as to avoid excessive fluid accumulation. Nitrogen intake should be carefully monitored in patients with impaired renal function. Aminosyn II 3.5% in 25% Dextrose (amino acid injection in dextrose injection) Injection is indicated for long-term total parenteral nutrition and whenever it is essential to provide, together with amino acids, adequate amounts of exogenous calories. Concentrated dextrose is an effective source of such calories. Such strongly hypertonic nutrient solutions should be administered only through an indwelling catheter with the tip located in a large vein: i.e., the superior vena cava. SPECIAL PRECAUTIONS FOR CENTRAL INFUSIONS ADMINISTRATION BY CENTRAL VENOUS CATHETER SHOULD BE USED ONLY BY THOSE FAMILIAR WITH THIS TECHNIQUE AND ITS COMPLICATIONS

Source: http://www.rxlist.com

Health Services in Toronto

Drug Database Online

Welcome to WebHealthNetwork an online drug guide and dictionary, here you can get drug information and definitaions for most popular pharmaceutical and medicinal drugs, and specifically Aminosyn II 3.5% in 25% Dextrose. Find what medications you are taking today.